BRISTOL-MYERS SQUIBB COMPANY

Bristol-Myers Squibb Company specializes in the manufacturing of advanced pharmaceutical preparations, with a demonstrated focus on complex cell and gene therapies, immunomodulatory agents, and transplant-related biologics. Their technical expertise includes the production of FDA-regulated injectable formulations such as ABECMA, BREYANZI, CAMZYOS, and REVLIMID—therapies used in hematologic malignancies and transplant conditioning regimens. The company possesses deep capabilities in aseptic manufacturing, cold chain logistics, and compliance with cGMP standards for high-potency, patient-specific biologics. Their ability to deliver emergency and routine infusions of novel therapeutics underscores operational agility in time-sensitive, mission-critical supply chains for life-saving treatments. The Department of Veterans Affairs is the sole recurring federal customer, consistently procuring specialized pharmaceuticals for veteran oncology, transplant, and hematologic care programs. This sustained engagement indicates a trusted, long-term relationship centered on reliable supply of high-complexity medications for VA medical centers and specialty clinics, particularly those serving post-transplant and CAR-T therapy patient populations. The primary NAICS code 325412 reflects core competency in pharmaceutical preparation manufacturing, with a narrow vertical specialization in oncology and immunotherapy products. The company’s market positioning is defined by its capacity to produce and distribute highly regulated, patient-specific biologics under stringent quality controls, serving a niche but critical segment of the federal healthcare supply chain. As a 2L entity headquartered in Lawrenceville, New Jersey, Bristol-Myers Squibb operates as a large-scale manufacturer with no government certifications listed. Its geographic presence is anchored in the U.S. biopharmaceutical corridor, with federal market positioning rooted in its ability to meet the VA’s demanding requirements for specialty drug availability, stability, and traceability in complex therapeutic categories.